Cell Based Assays – EQELS
Electrophoretic quasi elastic light scattering (EQELS™) is an emerging technology that can detect cellular metabolic changes reflected in the cells surface.
EQELS can be adapted in many different ways to provide clinically relevant information. These assays can be used to evaluate any particles that have been suspended in liquid media. The particles may be intact cells, fragments of cells (micro particles), ligand bound to the particles, or dimerized combinations of cells and micro particles. EQELS detects the subtle changes on the particle’s surface between resting, activated, apoptotic and ligand bound states. This can answer clinically relevant questions such as:
1. Is the drug you are taking adequately inhibiting your platelets?
2. Is your chemotherapy actually killing the cancer cells?
3. Do you have circulating activated platelets, lymphocytes, etc.?
4. Does the antibiotic you are taking actually bind to and kill the infectious agent causing your illness?
5. So your genomic profile shows several different genetic abnormalities. Which one is relevant to you? Cell-based assays can be employed to help sort out, which mutation is relevant.
6. Surface binding site (surface receptor) mapping.
EQELS has proven efficacy in binding site mapping, procoagulant factor binding, platelet surface activation of procoagulants, surface receptor inhibition, platelet membrane modification by ingested omega-3 fatty acids.
Platelet Function Assays
Currently available platelet function tests require a normal platelet count and depend on platelet aggregation as the assay end point. EQELS is a reliable method to assess relevant platelet function that is assessable to all platelet counts, while being accurate, inexpensive, and with a rapid turn-around time. Thus EQELS is a convenient method to test for platelet inhibition by drugs like clopidogrel and aspirin.
If platelets fail to activate when challenged with the appropriate platelet activator, it indicates that the antiplatelet drug is effective. EQELS CLIA approved platelet assay (REACT-P) provides diagnostic capabilities currently unavailable for the severely thrombocytopenic or thrombophilic patients. The method is so sensitive that a ligand concentration as low as 10-17 M can be detected when bound to the platelet. Thus, EQELS by taking advantage of the electrokinetics of a platelet from resting to activation and with interaction of diverse ligands provides highly accurate data in a short period of time that is not currently available from standard methods.
Please email us for more information at firstname.lastname@example.org.